pirmenol

Pirmenol is a Class Ia antiarrhythmic agent primarily used for the management of ventricular and supraventricular arrhythmias, including atrial fibrillation. Originally developed by Warner-Lambert (Parke-Davis), it is characterized by a complex electrophysiological profile that involves the blockade of fast sodium channels ($I_{Na}$), transient outward potassium channels ($I_{to}$), and acetylcholine-activated potassium channels ($I_{KAch}$), which collectively result in the prolongation of cardiac action potential duration and refractory periods. Unlike some other Class I agents, pirmenol also exhibits moderate L-type calcium channel blocking activity and significant anticholinergic (muscarinic receptor antagonist) properties. It has been primarily marketed and studied in Japan, where therapeutic drug monitoring is often employed due to its narrow therapeutic window and inter-individual pharmacokinetic variability.

Brand names

Pimenol

Other names

pirmenol hydrochloride